QQQ   444.96 (-0.15%)
AAPL   174.39 (-2.93%)
MSFT   415.73 (+0.06%)
META   500.37 (-0.38%)
GOOGL   132.58 (-3.33%)
AMZN   178.10 (-0.07%)
TSLA   187.42 (-7.51%)
NVDA   871.13 (+5.88%)
NIO   5.30 (-8.30%)
AMD   207.71 (+2.50%)
BABA   71.91 (-3.63%)
T   16.79 (-1.12%)
F   12.86 (+3.29%)
MU   96.75 (+1.68%)
CGC   3.01 (-6.23%)
GE   160.76 (+1.33%)
DIS   113.65 (+1.52%)
AMC   4.31 (-1.15%)
PFE   25.69 (-3.38%)
PYPL   59.84 (-1.16%)
XOM   104.50 (-1.27%)
QQQ   444.96 (-0.15%)
AAPL   174.39 (-2.93%)
MSFT   415.73 (+0.06%)
META   500.37 (-0.38%)
GOOGL   132.58 (-3.33%)
AMZN   178.10 (-0.07%)
TSLA   187.42 (-7.51%)
NVDA   871.13 (+5.88%)
NIO   5.30 (-8.30%)
AMD   207.71 (+2.50%)
BABA   71.91 (-3.63%)
T   16.79 (-1.12%)
F   12.86 (+3.29%)
MU   96.75 (+1.68%)
CGC   3.01 (-6.23%)
GE   160.76 (+1.33%)
DIS   113.65 (+1.52%)
AMC   4.31 (-1.15%)
PFE   25.69 (-3.38%)
PYPL   59.84 (-1.16%)
XOM   104.50 (-1.27%)
QQQ   444.96 (-0.15%)
AAPL   174.39 (-2.93%)
MSFT   415.73 (+0.06%)
META   500.37 (-0.38%)
GOOGL   132.58 (-3.33%)
AMZN   178.10 (-0.07%)
TSLA   187.42 (-7.51%)
NVDA   871.13 (+5.88%)
NIO   5.30 (-8.30%)
AMD   207.71 (+2.50%)
BABA   71.91 (-3.63%)
T   16.79 (-1.12%)
F   12.86 (+3.29%)
MU   96.75 (+1.68%)
CGC   3.01 (-6.23%)
GE   160.76 (+1.33%)
DIS   113.65 (+1.52%)
AMC   4.31 (-1.15%)
PFE   25.69 (-3.38%)
PYPL   59.84 (-1.16%)
XOM   104.50 (-1.27%)
QQQ   444.96 (-0.15%)
AAPL   174.39 (-2.93%)
MSFT   415.73 (+0.06%)
META   500.37 (-0.38%)
GOOGL   132.58 (-3.33%)
AMZN   178.10 (-0.07%)
TSLA   187.42 (-7.51%)
NVDA   871.13 (+5.88%)
NIO   5.30 (-8.30%)
AMD   207.71 (+2.50%)
BABA   71.91 (-3.63%)
T   16.79 (-1.12%)
F   12.86 (+3.29%)
MU   96.75 (+1.68%)
CGC   3.01 (-6.23%)
GE   160.76 (+1.33%)
DIS   113.65 (+1.52%)
AMC   4.31 (-1.15%)
PFE   25.69 (-3.38%)
PYPL   59.84 (-1.16%)
XOM   104.50 (-1.27%)

Tourmaline Bio (TRML) Stock Forecast & Price Target

$38.56
-4.03 (-9.46%)
(As of 02:03 PM ET)

Tourmaline Bio Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 6 Analyst Ratings

Analysts' Consensus Price Target

$49.75
29.02% Upside
High Forecast$65.00
Average Forecast$49.75
Low Forecast$41.00
TypeCurrent Forecast
3/5/23 to 3/4/24
1 Month Ago
2/3/23 to 2/3/24
3 Months Ago
12/5/22 to 12/5/23
1 Year Ago
3/5/22 to 3/5/23
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
6 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$49.75$49.75$52.67N/A
Predicted Upside29.02% Upside219.32% Upside265.57% UpsideN/A
Get Tourmaline Bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.


TRML Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TRML Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Tourmaline Bio Stock vs. The Competition

TypeTourmaline BioMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside16.81% Upside1,091.16% Upside6.76% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/15/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$41.00+114.66%
12/7/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
12/4/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
11/17/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$43.00+160.92%
10/31/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+236.70%
10/25/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$65.00+446.68%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:22 PM ET.












TRML Price Target - Frequently Asked Questions

What is Tourmaline Bio's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Tourmaline Bio stock is Buy based on the current 6 buy ratings for TRML. The average twelve-month price prediction for Tourmaline Bio is $49.75 with a high price target of $65.00 and a low price target of $41.00. Learn more on TRML's analyst rating history.

Do Wall Street analysts like Tourmaline Bio more than its competitors?

Analysts like Tourmaline Bio more than other Medical companies. The consensus rating for Tourmaline Bio is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how TRML compares to other companies.

Does Tourmaline Bio's stock price have much upside?

According to analysts, Tourmaline Bio's stock has a predicted upside of 219.32% based on their 12-month stock forecasts.

What analysts cover Tourmaline Bio?

Tourmaline Bio has been rated by Jefferies Financial Group, and Leerink Partnrs in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:TRML) was last updated on 3/4/2024 by MarketBeat.com Staff